![]() ![]() ![]() ![]() All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Some statements in this release may contain forward-looking information. I look forward to working with Leslie through these difficult market conditions to build Tetra into a successful pharmaceutical company," said Dr. Leslie has all the skills needed to bring Tetra to its next phase of growth. "We were very fortunate to find a CFO with experience in Canadian TSX-listed biotechnology companies. Auld is an analytical, strategic, and solutions-oriented finance professional who combines strong planning, organizational, and communication skills with proven ability to lead high-level operations and interact with senior management and Board of Directors. She has held executive positions in biotechnology companies developing investigational new drugs, which is the core activity of Tetra. publicly listed companies in the pharmaceutical and diagnostic technology industries. Auld is a seasoned Financial Executive with over 30 years of relevant experience, including a background in Canadian and U.S. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1) a leader in cannabinoid-derived drug discovery and development is pleased to announce the appointment of Leslie Auld, H.BSc, MBA, CPA, as Chief Financial Officer and member of the Company's executive team, effective May 30, 2022. OTTAWA, ON, /PRNewswire/ - Tetra Bio-Pharma Inc. ![]()
0 Comments
Leave a Reply. |